Review




Structured Review

Proteintech orm1
Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood <t>ORM1</t> in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.
Orm1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/orm1/product/Proteintech
Average 93 stars, based on 17 article reviews
orm1 - by Bioz Stars, 2026-06
93/100 stars

Images

1) Product Images from "ORM2 protects against acute pancreatitis by inhibiting premature activation of pancreatic enzymes"

Article Title: ORM2 protects against acute pancreatitis by inhibiting premature activation of pancreatic enzymes

Journal: Translational Gastroenterology and Hepatology

doi: 10.21037/tgh-25-106

Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood ORM1 in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.
Figure Legend Snippet: Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood ORM1 in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.

Techniques Used: Expressing, Transformation Assay, Control, Western Blot, Two Tailed Test



Similar Products

93
Proteintech orm1
Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood <t>ORM1</t> in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.
Orm1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/orm1/product/Proteintech
Average 93 stars, based on 1 article reviews
orm1 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

86
Obio Technology Corp Ltd pmirreport orm1
Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood <t>ORM1</t> in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.
Pmirreport Orm1, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pmirreport orm1/product/Obio Technology Corp Ltd
Average 86 stars, based on 1 article reviews
pmirreport orm1 - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Jingmei Biotech Co Ltd orm1 elisa kit
<t>ORM1</t> levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) <t>ELISA</t> analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Orm1 Elisa Kit, supplied by Jingmei Biotech Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/orm1 elisa kit/product/Jingmei Biotech Co Ltd
Average 86 stars, based on 1 article reviews
orm1 elisa kit - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

93
Proteintech anti orm1 antibody
<t>ORM1</t> levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) <t>ELISA</t> analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Anti Orm1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti orm1 antibody/product/Proteintech
Average 93 stars, based on 1 article reviews
anti orm1 antibody - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Proteintech immunofluorescence staining with orm1
<t>ORM1</t> levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) <t>Immunofluorescence</t> co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Immunofluorescence Staining With Orm1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunofluorescence staining with orm1/product/Proteintech
Average 93 stars, based on 1 article reviews
immunofluorescence staining with orm1 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Proteintech orm1 antibody
<t>ORM1</t> levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Orm1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/orm1 antibody/product/Proteintech
Average 93 stars, based on 1 article reviews
orm1 antibody - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

86
Affinity Biosciences anti orm1
<t>ORM1</t> levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Anti Orm1, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti orm1/product/Affinity Biosciences
Average 86 stars, based on 1 article reviews
anti orm1 - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

90
Shanghai GenePharma orm1 sirna
<t>ORM1</t> levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Orm1 Sirna, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/orm1 sirna/product/Shanghai GenePharma
Average 90 stars, based on 1 article reviews
orm1 sirna - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

93
Proteintech elisa kit
Proteomic analysis of the synovial fluid (SF) samples from patients with different stages of temporomandibular joint osteoarthritis (TMJOA). A) Flow diagram for patient inclusion and grouping. B) Photograph showing joint fluid collection during arthroscopic surgery. C) Flow diagram for the proteomic analysis of SF samples. D) Principal component analysis of SF samples. E) Top 10 genes that showed an upward trend and top 10 genes that showed a downward trend in the three groups. F) Orosomucoid <t>1</t> <t>(ORM1)</t> expression in patients with different grades of TMJOA, including Mild (n = 21), Moderate (n = 27), and Severe (n = 15) groups. Data is expressed as mean ± SD and analyzed using one‐way analysis of variance (ANOVA) followed by Tukey's post‐hoc test. G) ORM1 expression in patients with pain (n = 30) or without pain (n = 26). Data is expressed as mean ± SD and analyzed using unpaired Student's t test (two‐tailed). H) ORM1 expression in patients with different degrees of maximum interincisal opening (MIO). Data in MIO ≤ 25 mm (n = 10), MIO 26–35 mm (n = 20), and MIO ≥ 36 mm (n = 29) groups are expressed as mean ± SD and analyzed using one‐way ANOVA followed by Tukey's post‐hoc test. I) ORM1 expression in patients with sleep bruxism (n = 26) or without sleep bruxism (n = 23). Data is expressed as mean ± SD and analyzed using unpaired Student's t test (two‐tailed). J) ORM1 concentration in SF samples detected by <t>ELISA</t> assay in Mild (n = 5), Moderate (n = 5), and Severe (n = 5) groups. Data is expressed as mean ± SD and analyzed using one‐way ANOVA followed by Tukey's post‐hoc test. FOT, fraction of the total; * p < 0.05.
Elisa Kit, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/Proteintech
Average 93 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

Image Search Results


Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood ORM1 in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.

Journal: Translational Gastroenterology and Hepatology

Article Title: ORM2 protects against acute pancreatitis by inhibiting premature activation of pancreatic enzymes

doi: 10.21037/tgh-25-106

Figure Lengend Snippet: Reduced pancreatic ORM2 expression in AP. (A) Scatterplots showing log2 transformation of the normalized blood ORM1 in patients with MAP (n=57) and healthy controls (n=32). (B) Scatterplots showing log2 transformation of the normalized blood ORM2 in patients with MAP (n=57) and healthy controls (n=32). (C) The serum ORM in control and AP mice (n=6 per group). (D) Immunoblotting of ORM1 and ORM2 in serum from control and AP mice (n=6 per group). (E) Immunoblotting and quantitative analysis of ORM1 and ORM2 in pancreas from control and AP mice (n=6 per group). (F) Immunoblotting and quantitative analysis of ORM1 and ORM2 in liver from control and AP mice (n=6 per group). Data are presented as mean ± SEM. The groups were compared using unpaired two-tailed student’s t -test (*, P<0.05; ***, P<0.001; ****, P<0.0001). AP, acute pancreatitis; MAP, mild acute pancreatitis; ORM, orosomucoid; SEM, standard error of the mean.

Article Snippet: The antibodies used in this study are listed as follows: ORM1 (No. 16439-1-AP proteintech, Wuhan, China), ORM2 (No. P19652 , zenbio, Chengdu, China), GAPDH (No. A19056, ABclonal, Wuhan, China), HRP-conjugated Goat anti-Rabbit IgG (H+L) (No. AS014, ABclonal, Wuhan, China).

Techniques: Expressing, Transformation Assay, Control, Western Blot, Two Tailed Test

ORM1 levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Enzyme-linked Immunosorbent Assay, Control, Quantitative RT-PCR, Expressing, Western Blot, Immunofluorescence, Staining, Marker

Downregulation of ORM1 Significantly Mitigates LPS‐Induced Lung Injury in ARDS Rats. (A) Hematoxylin and eosin (H&E) staining revealssubstantial histopathological damage in lung tissues at 24 h post‐LPS induction and significant attenuation of LPS‐induced pulmonary injury following ORM1 knockdown. Scale bars: 200 μm. (B) Histopathological injury scores corresponding to H&E staining for lung injury assessment. (C) Pulmonary edema assessed by lung wet/dry weight ratio. Data represent mean ± SD ( n = 6). Significance in (B) and (C) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: Downregulation of ORM1 Significantly Mitigates LPS‐Induced Lung Injury in ARDS Rats. (A) Hematoxylin and eosin (H&E) staining revealssubstantial histopathological damage in lung tissues at 24 h post‐LPS induction and significant attenuation of LPS‐induced pulmonary injury following ORM1 knockdown. Scale bars: 200 μm. (B) Histopathological injury scores corresponding to H&E staining for lung injury assessment. (C) Pulmonary edema assessed by lung wet/dry weight ratio. Data represent mean ± SD ( n = 6). Significance in (B) and (C) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group.

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Staining, Knockdown, Control

ORM1 Suppression Ameliorates Alveolar Hypercoagulation and Fibrinolysis Inhibition In Vivo. (A–C) ELISA quantification of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) showing: Significant elevation of all three biomarkers at 24 h post‐LPS airway nebulization inhalation compared to controls, and marked reduction in their levels following ORM1 knockdown. (D–F) qRT‐PCR analysis reveals: Significant elevation of ORM1, TF, and PAI‐1 mRNA levels in LPS‐induced ARDS lung tissues compared to control, Marked downregulation of these transcripts following ORM1 knockdown. (J) Representative Western blots showing upregulated ORM1, TF, and PAI‐1 protein expression in lung tissues at 24 h post‐LPS induction, with significant reduction following ORM1 knockdown, Quantitative densitometric analysis of (G) ORM1, (H) TF, and (I) PAI‐1 protein levels normalized to GAPDH. (K) Collagen III deposition in lung parenchyma visualized by immunohistochemistry (brown staining indicates positive expression). Scale bars: 300 μm. Data represent mean ± SD ( n = 6), Significance in (A–I) were calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Suppression Ameliorates Alveolar Hypercoagulation and Fibrinolysis Inhibition In Vivo. (A–C) ELISA quantification of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) showing: Significant elevation of all three biomarkers at 24 h post‐LPS airway nebulization inhalation compared to controls, and marked reduction in their levels following ORM1 knockdown. (D–F) qRT‐PCR analysis reveals: Significant elevation of ORM1, TF, and PAI‐1 mRNA levels in LPS‐induced ARDS lung tissues compared to control, Marked downregulation of these transcripts following ORM1 knockdown. (J) Representative Western blots showing upregulated ORM1, TF, and PAI‐1 protein expression in lung tissues at 24 h post‐LPS induction, with significant reduction following ORM1 knockdown, Quantitative densitometric analysis of (G) ORM1, (H) TF, and (I) PAI‐1 protein levels normalized to GAPDH. (K) Collagen III deposition in lung parenchyma visualized by immunohistochemistry (brown staining indicates positive expression). Scale bars: 300 μm. Data represent mean ± SD ( n = 6), Significance in (A–I) were calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Inhibition, In Vivo, Enzyme-linked Immunosorbent Assay, Knockdown, Quantitative RT-PCR, Control, Western Blot, Expressing, Immunohistochemistry, Staining

ORM1 Enhances NF‐κB Signaling Pathway Activation In Vivo. (A) The Western blot method was used to detect the protein expression levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 in the lung tissues of rats in each group, with quantitative densitometry showing the expression levels of total IKKβ (B) and total p65 (D) in the lung tissues of each group of rats were not statistically significant, and the expression levels of phosphorylated IKKβ (C) and phosphorylated p65 (E) in the lung tissues of rats induced by LPS increased, while those in the lung tissues of rats induced by LPS decreased after knockdown of ORM1. Data represent mean ± SD ( n = 6). Significance in (B–E) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant ( p > 0.05).

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Enhances NF‐κB Signaling Pathway Activation In Vivo. (A) The Western blot method was used to detect the protein expression levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 in the lung tissues of rats in each group, with quantitative densitometry showing the expression levels of total IKKβ (B) and total p65 (D) in the lung tissues of each group of rats were not statistically significant, and the expression levels of phosphorylated IKKβ (C) and phosphorylated p65 (E) in the lung tissues of rats induced by LPS increased, while those in the lung tissues of rats induced by LPS decreased after knockdown of ORM1. Data represent mean ± SD ( n = 6). Significance in (B–E) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant ( p > 0.05).

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Activation Assay, In Vivo, Western Blot, Expressing, Knockdown

ORM1 Promotes TF and PAI‐1 Expression in LPS‐Stimulated AEC II Cells. (A–C) qRT‐PCR analysis showed that, compared with the control group, the mRNA levels of ORM1, TF, and PAI‐1 in AEC II cells induced by LPS for 24 h were significantly increased, and the levels of these indicators were down‐regulated after the knockdown of ORM1. (D) Representative Western blot results showed that the protein expressions of ORM1, TF, and PAI‐1 in AEC II cells were upregulated after 24 h of LPS induction and significantly decreased after the knockdown of ORM1. Quantitative density analysis normalized the protein levels of (E) ORM1, (F) TF, and (G) PAI‐1 to GAPDH. Data represent mean ± SD ( n = 6). Significance in (A–C, E–G) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Promotes TF and PAI‐1 Expression in LPS‐Stimulated AEC II Cells. (A–C) qRT‐PCR analysis showed that, compared with the control group, the mRNA levels of ORM1, TF, and PAI‐1 in AEC II cells induced by LPS for 24 h were significantly increased, and the levels of these indicators were down‐regulated after the knockdown of ORM1. (D) Representative Western blot results showed that the protein expressions of ORM1, TF, and PAI‐1 in AEC II cells were upregulated after 24 h of LPS induction and significantly decreased after the knockdown of ORM1. Quantitative density analysis normalized the protein levels of (E) ORM1, (F) TF, and (G) PAI‐1 to GAPDH. Data represent mean ± SD ( n = 6). Significance in (A–C, E–G) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Expressing, Quantitative RT-PCR, Control, Knockdown, Western Blot

ORM1 Enhances TF and PAI‐1 expression maybe through the NF‐κB pathway. (A) Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 were assessed using Western Blot analysis, followed by semiquantitative analysis (B–E) after ORM1 knockdown. Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), total p65, TF, and PAI‐1 were assessed using Western Blot analysis (F), followed by semiquantitative analysis (G–N) after NF‐κB inhibitor benzoxathiole treatment. Data represent mean ± SD ( n = 3). Significance in (B–E, G–N) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: Not significant ( p > 0.05).

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Enhances TF and PAI‐1 expression maybe through the NF‐κB pathway. (A) Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 were assessed using Western Blot analysis, followed by semiquantitative analysis (B–E) after ORM1 knockdown. Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), total p65, TF, and PAI‐1 were assessed using Western Blot analysis (F), followed by semiquantitative analysis (G–N) after NF‐κB inhibitor benzoxathiole treatment. Data represent mean ± SD ( n = 3). Significance in (B–E, G–N) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: Not significant ( p > 0.05).

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Expressing, Western Blot, Knockdown

ORM1 Directly Activates the NF‐κB Pathway in LPS‐Exposed AEC II Cells. (A) Cell immunofluorescence co‐staining of ORM1 (red) and phosphorylated IKKβ (p‐IKKβ, green). The yellow signal (white arrow) indicates the co‐localization of ORM1/p‐IKKβ. After 24 h of LPS induction, the expression and co‐expression of ORM1 and p‐IKKβ in AEC II cells increased. After knockout of ORM1, In LPS‐induced AECII cells, the expressions of ORM1, p‐IKKβ and their co‐expressions were all decreased. (B) Co‐expression of ORM1 and p‐IKKβ in LPS‐Induced AEC II cells following NF‐κB pathway inhibitor (benzoxathiole) treatment were decreased. The yellow areas, indicated by white arrows, represent regions of co‐localization between ORM1 and p‐IKKβ (scale bar: 30 μm). (C and D) The immunoprecipitation results show that in LPS‐induced AEC II cells, ORM1 interacts with p‐IKKB.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Directly Activates the NF‐κB Pathway in LPS‐Exposed AEC II Cells. (A) Cell immunofluorescence co‐staining of ORM1 (red) and phosphorylated IKKβ (p‐IKKβ, green). The yellow signal (white arrow) indicates the co‐localization of ORM1/p‐IKKβ. After 24 h of LPS induction, the expression and co‐expression of ORM1 and p‐IKKβ in AEC II cells increased. After knockout of ORM1, In LPS‐induced AECII cells, the expressions of ORM1, p‐IKKβ and their co‐expressions were all decreased. (B) Co‐expression of ORM1 and p‐IKKβ in LPS‐Induced AEC II cells following NF‐κB pathway inhibitor (benzoxathiole) treatment were decreased. The yellow areas, indicated by white arrows, represent regions of co‐localization between ORM1 and p‐IKKβ (scale bar: 30 μm). (C and D) The immunoprecipitation results show that in LPS‐induced AEC II cells, ORM1 interacts with p‐IKKB.

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Immunofluorescence, Staining, Expressing, Knock-Out, Immunoprecipitation

Concentrations of ORM1 in BALF Are Significantly Elevated in Patients with ARDS. (A) ORM1, (B) TF, and (C) PAI‐1 concentrations in BALF from patients with ARDS ( n = 28) and non‐ARDS ( n = 26) were measured using specific human ORM1, TF, and PAI‐1 enzyme‐linked immunosorbent assay (ELISA) kits. (D) Oxygenation index, expressed as the ratio of arterial oxygen partial pressure to oxygen concentration (P/F), in ARDS patients ( n = 28) and non‐ARDS patients ( n = 26). Correlations between BALF concentrations of ORM1 and those of (E) TF, (F) PAI‐1, and (G) P/F ratio in patients with ARDS are shown. Data represent mean ± SD. Significance in (A–D) was calculated using an independent t test; significance in (A–D) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test, and (E–G) were evaluated with Pearson's correlation coefficients. **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: Concentrations of ORM1 in BALF Are Significantly Elevated in Patients with ARDS. (A) ORM1, (B) TF, and (C) PAI‐1 concentrations in BALF from patients with ARDS ( n = 28) and non‐ARDS ( n = 26) were measured using specific human ORM1, TF, and PAI‐1 enzyme‐linked immunosorbent assay (ELISA) kits. (D) Oxygenation index, expressed as the ratio of arterial oxygen partial pressure to oxygen concentration (P/F), in ARDS patients ( n = 28) and non‐ARDS patients ( n = 26). Correlations between BALF concentrations of ORM1 and those of (E) TF, (F) PAI‐1, and (G) P/F ratio in patients with ARDS are shown. Data represent mean ± SD. Significance in (A–D) was calculated using an independent t test; significance in (A–D) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test, and (E–G) were evaluated with Pearson's correlation coefficients. **** p < 0.0001.

Article Snippet: Concentrations of ORM1, TF, and PAI‐1 were measured in human and rat plasma and BALF with a commercially available ORM1 ELISA kit (Jingmei Biotechnology Co. LTD, Jiangsu, China).

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay

ORM1 levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Enzyme-linked Immunosorbent Assay, Control, Quantitative RT-PCR, Expressing, Western Blot, Immunofluorescence, Staining, Marker

Downregulation of ORM1 Significantly Mitigates LPS‐Induced Lung Injury in ARDS Rats. (A) Hematoxylin and eosin (H&E) staining revealssubstantial histopathological damage in lung tissues at 24 h post‐LPS induction and significant attenuation of LPS‐induced pulmonary injury following ORM1 knockdown. Scale bars: 200 μm. (B) Histopathological injury scores corresponding to H&E staining for lung injury assessment. (C) Pulmonary edema assessed by lung wet/dry weight ratio. Data represent mean ± SD ( n = 6). Significance in (B) and (C) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: Downregulation of ORM1 Significantly Mitigates LPS‐Induced Lung Injury in ARDS Rats. (A) Hematoxylin and eosin (H&E) staining revealssubstantial histopathological damage in lung tissues at 24 h post‐LPS induction and significant attenuation of LPS‐induced pulmonary injury following ORM1 knockdown. Scale bars: 200 μm. (B) Histopathological injury scores corresponding to H&E staining for lung injury assessment. (C) Pulmonary edema assessed by lung wet/dry weight ratio. Data represent mean ± SD ( n = 6). Significance in (B) and (C) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group.

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Staining, Knockdown, Control

ORM1 Suppression Ameliorates Alveolar Hypercoagulation and Fibrinolysis Inhibition In Vivo. (A–C) ELISA quantification of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) showing: Significant elevation of all three biomarkers at 24 h post‐LPS airway nebulization inhalation compared to controls, and marked reduction in their levels following ORM1 knockdown. (D–F) qRT‐PCR analysis reveals: Significant elevation of ORM1, TF, and PAI‐1 mRNA levels in LPS‐induced ARDS lung tissues compared to control, Marked downregulation of these transcripts following ORM1 knockdown. (J) Representative Western blots showing upregulated ORM1, TF, and PAI‐1 protein expression in lung tissues at 24 h post‐LPS induction, with significant reduction following ORM1 knockdown, Quantitative densitometric analysis of (G) ORM1, (H) TF, and (I) PAI‐1 protein levels normalized to GAPDH. (K) Collagen III deposition in lung parenchyma visualized by immunohistochemistry (brown staining indicates positive expression). Scale bars: 300 μm. Data represent mean ± SD ( n = 6), Significance in (A–I) were calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Suppression Ameliorates Alveolar Hypercoagulation and Fibrinolysis Inhibition In Vivo. (A–C) ELISA quantification of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) showing: Significant elevation of all three biomarkers at 24 h post‐LPS airway nebulization inhalation compared to controls, and marked reduction in their levels following ORM1 knockdown. (D–F) qRT‐PCR analysis reveals: Significant elevation of ORM1, TF, and PAI‐1 mRNA levels in LPS‐induced ARDS lung tissues compared to control, Marked downregulation of these transcripts following ORM1 knockdown. (J) Representative Western blots showing upregulated ORM1, TF, and PAI‐1 protein expression in lung tissues at 24 h post‐LPS induction, with significant reduction following ORM1 knockdown, Quantitative densitometric analysis of (G) ORM1, (H) TF, and (I) PAI‐1 protein levels normalized to GAPDH. (K) Collagen III deposition in lung parenchyma visualized by immunohistochemistry (brown staining indicates positive expression). Scale bars: 300 μm. Data represent mean ± SD ( n = 6), Significance in (A–I) were calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Inhibition, In Vivo, Enzyme-linked Immunosorbent Assay, Knockdown, Quantitative RT-PCR, Control, Western Blot, Expressing, Immunohistochemistry, Staining

ORM1 Enhances NF‐κB Signaling Pathway Activation In Vivo. (A) The Western blot method was used to detect the protein expression levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 in the lung tissues of rats in each group, with quantitative densitometry showing the expression levels of total IKKβ (B) and total p65 (D) in the lung tissues of each group of rats were not statistically significant, and the expression levels of phosphorylated IKKβ (C) and phosphorylated p65 (E) in the lung tissues of rats induced by LPS increased, while those in the lung tissues of rats induced by LPS decreased after knockdown of ORM1. Data represent mean ± SD ( n = 6). Significance in (B–E) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant ( p > 0.05).

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Enhances NF‐κB Signaling Pathway Activation In Vivo. (A) The Western blot method was used to detect the protein expression levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 in the lung tissues of rats in each group, with quantitative densitometry showing the expression levels of total IKKβ (B) and total p65 (D) in the lung tissues of each group of rats were not statistically significant, and the expression levels of phosphorylated IKKβ (C) and phosphorylated p65 (E) in the lung tissues of rats induced by LPS increased, while those in the lung tissues of rats induced by LPS decreased after knockdown of ORM1. Data represent mean ± SD ( n = 6). Significance in (B–E) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant ( p > 0.05).

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Activation Assay, In Vivo, Western Blot, Expressing, Knockdown

ORM1 Promotes TF and PAI‐1 Expression in LPS‐Stimulated AEC II Cells. (A–C) qRT‐PCR analysis showed that, compared with the control group, the mRNA levels of ORM1, TF, and PAI‐1 in AEC II cells induced by LPS for 24 h were significantly increased, and the levels of these indicators were down‐regulated after the knockdown of ORM1. (D) Representative Western blot results showed that the protein expressions of ORM1, TF, and PAI‐1 in AEC II cells were upregulated after 24 h of LPS induction and significantly decreased after the knockdown of ORM1. Quantitative density analysis normalized the protein levels of (E) ORM1, (F) TF, and (G) PAI‐1 to GAPDH. Data represent mean ± SD ( n = 6). Significance in (A–C, E–G) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Promotes TF and PAI‐1 Expression in LPS‐Stimulated AEC II Cells. (A–C) qRT‐PCR analysis showed that, compared with the control group, the mRNA levels of ORM1, TF, and PAI‐1 in AEC II cells induced by LPS for 24 h were significantly increased, and the levels of these indicators were down‐regulated after the knockdown of ORM1. (D) Representative Western blot results showed that the protein expressions of ORM1, TF, and PAI‐1 in AEC II cells were upregulated after 24 h of LPS induction and significantly decreased after the knockdown of ORM1. Quantitative density analysis normalized the protein levels of (E) ORM1, (F) TF, and (G) PAI‐1 to GAPDH. Data represent mean ± SD ( n = 6). Significance in (A–C, E–G) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Expressing, Quantitative RT-PCR, Control, Knockdown, Western Blot

ORM1 Enhances TF and PAI‐1 expression maybe through the NF‐κB pathway. (A) Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 were assessed using Western Blot analysis, followed by semiquantitative analysis (B–E) after ORM1 knockdown. Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), total p65, TF, and PAI‐1 were assessed using Western Blot analysis (F), followed by semiquantitative analysis (G–N) after NF‐κB inhibitor benzoxathiole treatment. Data represent mean ± SD ( n = 3). Significance in (B–E, G–N) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: Not significant ( p > 0.05).

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Enhances TF and PAI‐1 expression maybe through the NF‐κB pathway. (A) Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 were assessed using Western Blot analysis, followed by semiquantitative analysis (B–E) after ORM1 knockdown. Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), total p65, TF, and PAI‐1 were assessed using Western Blot analysis (F), followed by semiquantitative analysis (G–N) after NF‐κB inhibitor benzoxathiole treatment. Data represent mean ± SD ( n = 3). Significance in (B–E, G–N) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: Not significant ( p > 0.05).

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Expressing, Western Blot, Knockdown

ORM1 Directly Activates the NF‐κB Pathway in LPS‐Exposed AEC II Cells. (A) Cell immunofluorescence co‐staining of ORM1 (red) and phosphorylated IKKβ (p‐IKKβ, green). The yellow signal (white arrow) indicates the co‐localization of ORM1/p‐IKKβ. After 24 h of LPS induction, the expression and co‐expression of ORM1 and p‐IKKβ in AEC II cells increased. After knockout of ORM1, In LPS‐induced AECII cells, the expressions of ORM1, p‐IKKβ and their co‐expressions were all decreased. (B) Co‐expression of ORM1 and p‐IKKβ in LPS‐Induced AEC II cells following NF‐κB pathway inhibitor (benzoxathiole) treatment were decreased. The yellow areas, indicated by white arrows, represent regions of co‐localization between ORM1 and p‐IKKβ (scale bar: 30 μm). (C and D) The immunoprecipitation results show that in LPS‐induced AEC II cells, ORM1 interacts with p‐IKKB.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Directly Activates the NF‐κB Pathway in LPS‐Exposed AEC II Cells. (A) Cell immunofluorescence co‐staining of ORM1 (red) and phosphorylated IKKβ (p‐IKKβ, green). The yellow signal (white arrow) indicates the co‐localization of ORM1/p‐IKKβ. After 24 h of LPS induction, the expression and co‐expression of ORM1 and p‐IKKβ in AEC II cells increased. After knockout of ORM1, In LPS‐induced AECII cells, the expressions of ORM1, p‐IKKβ and their co‐expressions were all decreased. (B) Co‐expression of ORM1 and p‐IKKβ in LPS‐Induced AEC II cells following NF‐κB pathway inhibitor (benzoxathiole) treatment were decreased. The yellow areas, indicated by white arrows, represent regions of co‐localization between ORM1 and p‐IKKβ (scale bar: 30 μm). (C and D) The immunoprecipitation results show that in LPS‐induced AEC II cells, ORM1 interacts with p‐IKKB.

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Immunofluorescence, Staining, Expressing, Knock-Out, Immunoprecipitation

Concentrations of ORM1 in BALF Are Significantly Elevated in Patients with ARDS. (A) ORM1, (B) TF, and (C) PAI‐1 concentrations in BALF from patients with ARDS ( n = 28) and non‐ARDS ( n = 26) were measured using specific human ORM1, TF, and PAI‐1 enzyme‐linked immunosorbent assay (ELISA) kits. (D) Oxygenation index, expressed as the ratio of arterial oxygen partial pressure to oxygen concentration (P/F), in ARDS patients ( n = 28) and non‐ARDS patients ( n = 26). Correlations between BALF concentrations of ORM1 and those of (E) TF, (F) PAI‐1, and (G) P/F ratio in patients with ARDS are shown. Data represent mean ± SD. Significance in (A–D) was calculated using an independent t test; significance in (A–D) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test, and (E–G) were evaluated with Pearson's correlation coefficients. **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: Concentrations of ORM1 in BALF Are Significantly Elevated in Patients with ARDS. (A) ORM1, (B) TF, and (C) PAI‐1 concentrations in BALF from patients with ARDS ( n = 28) and non‐ARDS ( n = 26) were measured using specific human ORM1, TF, and PAI‐1 enzyme‐linked immunosorbent assay (ELISA) kits. (D) Oxygenation index, expressed as the ratio of arterial oxygen partial pressure to oxygen concentration (P/F), in ARDS patients ( n = 28) and non‐ARDS patients ( n = 26). Correlations between BALF concentrations of ORM1 and those of (E) TF, (F) PAI‐1, and (G) P/F ratio in patients with ARDS are shown. Data represent mean ± SD. Significance in (A–D) was calculated using an independent t test; significance in (A–D) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test, and (E–G) were evaluated with Pearson's correlation coefficients. **** p < 0.0001.

Article Snippet: Lung tissue sections were blocked with sheep serum (Sorabio, Beijing, China) for 15 min at room temperature, and for double immunofluorescence staining with ORM1 (1:100 dilution, Proteintech, Wuhan, China) and SP‐C antibodies (1:100 dilution, Affinity Biosciences, USA) for detection.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay

ORM1 levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 levels are elevated in both BALF and lung tissues of LPS‐induced ARDS Rats. (A, D, E) ELISA analysis of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) from control and LPS‐treated rats at 24 h post‐induction. (B, E, H) qRT‐PCR analysis of ORM1, TF, and PAI‐1 mRNA expression levels in lung tissues of control and LPS‐treated rats at 24 h post‐induction. (J) Western blot analysis of ORM1, TF, and PAI‐1 protein expression in lung tissues of LPS‐induced ARDS rats at 24 h post‐induction, with quantitative densitometry shown in (G, C, I). (K) Immunofluorescence co‐staining for ORM1 (red) and alveolar type II cell marker surfactant protein C (SP‐C, green). Yellow signal (white arrow) indicates ORM1/SP‐C co‐localization. Scale bar: 300 μm. Data represent mean ± SD ( n = 6 per group). Significance in (A–J) was calculated using an independent t test; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Enzyme-linked Immunosorbent Assay, Control, Quantitative RT-PCR, Expressing, Western Blot, Immunofluorescence, Staining, Marker

Downregulation of ORM1 Significantly Mitigates LPS‐Induced Lung Injury in ARDS Rats. (A) Hematoxylin and eosin (H&E) staining revealssubstantial histopathological damage in lung tissues at 24 h post‐LPS induction and significant attenuation of LPS‐induced pulmonary injury following ORM1 knockdown. Scale bars: 200 μm. (B) Histopathological injury scores corresponding to H&E staining for lung injury assessment. (C) Pulmonary edema assessed by lung wet/dry weight ratio. Data represent mean ± SD ( n = 6). Significance in (B) and (C) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: Downregulation of ORM1 Significantly Mitigates LPS‐Induced Lung Injury in ARDS Rats. (A) Hematoxylin and eosin (H&E) staining revealssubstantial histopathological damage in lung tissues at 24 h post‐LPS induction and significant attenuation of LPS‐induced pulmonary injury following ORM1 knockdown. Scale bars: 200 μm. (B) Histopathological injury scores corresponding to H&E staining for lung injury assessment. (C) Pulmonary edema assessed by lung wet/dry weight ratio. Data represent mean ± SD ( n = 6). Significance in (B) and (C) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. Statistical significance: ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group.

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Staining, Knockdown, Control

ORM1 Suppression Ameliorates Alveolar Hypercoagulation and Fibrinolysis Inhibition In Vivo. (A–C) ELISA quantification of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) showing: Significant elevation of all three biomarkers at 24 h post‐LPS airway nebulization inhalation compared to controls, and marked reduction in their levels following ORM1 knockdown. (D–F) qRT‐PCR analysis reveals: Significant elevation of ORM1, TF, and PAI‐1 mRNA levels in LPS‐induced ARDS lung tissues compared to control, Marked downregulation of these transcripts following ORM1 knockdown. (J) Representative Western blots showing upregulated ORM1, TF, and PAI‐1 protein expression in lung tissues at 24 h post‐LPS induction, with significant reduction following ORM1 knockdown, Quantitative densitometric analysis of (G) ORM1, (H) TF, and (I) PAI‐1 protein levels normalized to GAPDH. (K) Collagen III deposition in lung parenchyma visualized by immunohistochemistry (brown staining indicates positive expression). Scale bars: 300 μm. Data represent mean ± SD ( n = 6), Significance in (A–I) were calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Suppression Ameliorates Alveolar Hypercoagulation and Fibrinolysis Inhibition In Vivo. (A–C) ELISA quantification of ORM1, TF, and PAI‐1 concentrations in bronchoalveolar lavage fluid (BALF) showing: Significant elevation of all three biomarkers at 24 h post‐LPS airway nebulization inhalation compared to controls, and marked reduction in their levels following ORM1 knockdown. (D–F) qRT‐PCR analysis reveals: Significant elevation of ORM1, TF, and PAI‐1 mRNA levels in LPS‐induced ARDS lung tissues compared to control, Marked downregulation of these transcripts following ORM1 knockdown. (J) Representative Western blots showing upregulated ORM1, TF, and PAI‐1 protein expression in lung tissues at 24 h post‐LPS induction, with significant reduction following ORM1 knockdown, Quantitative densitometric analysis of (G) ORM1, (H) TF, and (I) PAI‐1 protein levels normalized to GAPDH. (K) Collagen III deposition in lung parenchyma visualized by immunohistochemistry (brown staining indicates positive expression). Scale bars: 300 μm. Data represent mean ± SD ( n = 6), Significance in (A–I) were calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Inhibition, In Vivo, Enzyme-linked Immunosorbent Assay, Knockdown, Quantitative RT-PCR, Control, Western Blot, Expressing, Immunohistochemistry, Staining

ORM1 Enhances NF‐κB Signaling Pathway Activation In Vivo. (A) The Western blot method was used to detect the protein expression levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 in the lung tissues of rats in each group, with quantitative densitometry showing the expression levels of total IKKβ (B) and total p65 (D) in the lung tissues of each group of rats were not statistically significant, and the expression levels of phosphorylated IKKβ (C) and phosphorylated p65 (E) in the lung tissues of rats induced by LPS increased, while those in the lung tissues of rats induced by LPS decreased after knockdown of ORM1. Data represent mean ± SD ( n = 6). Significance in (B–E) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant ( p > 0.05).

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Enhances NF‐κB Signaling Pathway Activation In Vivo. (A) The Western blot method was used to detect the protein expression levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 in the lung tissues of rats in each group, with quantitative densitometry showing the expression levels of total IKKβ (B) and total p65 (D) in the lung tissues of each group of rats were not statistically significant, and the expression levels of phosphorylated IKKβ (C) and phosphorylated p65 (E) in the lung tissues of rats induced by LPS increased, while those in the lung tissues of rats induced by LPS decreased after knockdown of ORM1. Data represent mean ± SD ( n = 6). Significance in (B–E) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: Not significant ( p > 0.05).

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Activation Assay, In Vivo, Western Blot, Expressing, Knockdown

ORM1 Promotes TF and PAI‐1 Expression in LPS‐Stimulated AEC II Cells. (A–C) qRT‐PCR analysis showed that, compared with the control group, the mRNA levels of ORM1, TF, and PAI‐1 in AEC II cells induced by LPS for 24 h were significantly increased, and the levels of these indicators were down‐regulated after the knockdown of ORM1. (D) Representative Western blot results showed that the protein expressions of ORM1, TF, and PAI‐1 in AEC II cells were upregulated after 24 h of LPS induction and significantly decreased after the knockdown of ORM1. Quantitative density analysis normalized the protein levels of (E) ORM1, (F) TF, and (G) PAI‐1 to GAPDH. Data represent mean ± SD ( n = 6). Significance in (A–C, E–G) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Promotes TF and PAI‐1 Expression in LPS‐Stimulated AEC II Cells. (A–C) qRT‐PCR analysis showed that, compared with the control group, the mRNA levels of ORM1, TF, and PAI‐1 in AEC II cells induced by LPS for 24 h were significantly increased, and the levels of these indicators were down‐regulated after the knockdown of ORM1. (D) Representative Western blot results showed that the protein expressions of ORM1, TF, and PAI‐1 in AEC II cells were upregulated after 24 h of LPS induction and significantly decreased after the knockdown of ORM1. Quantitative density analysis normalized the protein levels of (E) ORM1, (F) TF, and (G) PAI‐1 to GAPDH. Data represent mean ± SD ( n = 6). Significance in (A–C, E–G) was calculated using the one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Expressing, Quantitative RT-PCR, Control, Knockdown, Western Blot

ORM1 Enhances TF and PAI‐1 expression maybe through the NF‐κB pathway. (A) Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 were assessed using Western Blot analysis, followed by semiquantitative analysis (B–E) after ORM1 knockdown. Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), total p65, TF, and PAI‐1 were assessed using Western Blot analysis (F), followed by semiquantitative analysis (G–N) after NF‐κB inhibitor benzoxathiole treatment. Data represent mean ± SD ( n = 3). Significance in (B–E, G–N) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: Not significant ( p > 0.05).

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Enhances TF and PAI‐1 expression maybe through the NF‐κB pathway. (A) Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), and total p65 were assessed using Western Blot analysis, followed by semiquantitative analysis (B–E) after ORM1 knockdown. Protein levels of phosphorylated IKKβ (p‐IKKβ), total IKKβ, phosphorylated p65 (p‐p65), total p65, TF, and PAI‐1 were assessed using Western Blot analysis (F), followed by semiquantitative analysis (G–N) after NF‐κB inhibitor benzoxathiole treatment. Data represent mean ± SD ( n = 3). Significance in (B–E, G–N) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test. *p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: Not significant ( p > 0.05).

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Expressing, Western Blot, Knockdown

ORM1 Directly Activates the NF‐κB Pathway in LPS‐Exposed AEC II Cells. (A) Cell immunofluorescence co‐staining of ORM1 (red) and phosphorylated IKKβ (p‐IKKβ, green). The yellow signal (white arrow) indicates the co‐localization of ORM1/p‐IKKβ. After 24 h of LPS induction, the expression and co‐expression of ORM1 and p‐IKKβ in AEC II cells increased. After knockout of ORM1, In LPS‐induced AECII cells, the expressions of ORM1, p‐IKKβ and their co‐expressions were all decreased. (B) Co‐expression of ORM1 and p‐IKKβ in LPS‐Induced AEC II cells following NF‐κB pathway inhibitor (benzoxathiole) treatment were decreased. The yellow areas, indicated by white arrows, represent regions of co‐localization between ORM1 and p‐IKKβ (scale bar: 30 μm). (C and D) The immunoprecipitation results show that in LPS‐induced AEC II cells, ORM1 interacts with p‐IKKB.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: ORM1 Directly Activates the NF‐κB Pathway in LPS‐Exposed AEC II Cells. (A) Cell immunofluorescence co‐staining of ORM1 (red) and phosphorylated IKKβ (p‐IKKβ, green). The yellow signal (white arrow) indicates the co‐localization of ORM1/p‐IKKβ. After 24 h of LPS induction, the expression and co‐expression of ORM1 and p‐IKKβ in AEC II cells increased. After knockout of ORM1, In LPS‐induced AECII cells, the expressions of ORM1, p‐IKKβ and their co‐expressions were all decreased. (B) Co‐expression of ORM1 and p‐IKKβ in LPS‐Induced AEC II cells following NF‐κB pathway inhibitor (benzoxathiole) treatment were decreased. The yellow areas, indicated by white arrows, represent regions of co‐localization between ORM1 and p‐IKKβ (scale bar: 30 μm). (C and D) The immunoprecipitation results show that in LPS‐induced AEC II cells, ORM1 interacts with p‐IKKB.

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Immunofluorescence, Staining, Expressing, Knock-Out, Immunoprecipitation

Concentrations of ORM1 in BALF Are Significantly Elevated in Patients with ARDS. (A) ORM1, (B) TF, and (C) PAI‐1 concentrations in BALF from patients with ARDS ( n = 28) and non‐ARDS ( n = 26) were measured using specific human ORM1, TF, and PAI‐1 enzyme‐linked immunosorbent assay (ELISA) kits. (D) Oxygenation index, expressed as the ratio of arterial oxygen partial pressure to oxygen concentration (P/F), in ARDS patients ( n = 28) and non‐ARDS patients ( n = 26). Correlations between BALF concentrations of ORM1 and those of (E) TF, (F) PAI‐1, and (G) P/F ratio in patients with ARDS are shown. Data represent mean ± SD. Significance in (A–D) was calculated using an independent t test; significance in (A–D) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test, and (E–G) were evaluated with Pearson's correlation coefficients. **** p < 0.0001.

Journal: The FASEB Journal

Article Title: Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF ‐ κB Signaling Pathway in LPS ‐Induced ARDS

doi: 10.1096/fj.202502459RR

Figure Lengend Snippet: Concentrations of ORM1 in BALF Are Significantly Elevated in Patients with ARDS. (A) ORM1, (B) TF, and (C) PAI‐1 concentrations in BALF from patients with ARDS ( n = 28) and non‐ARDS ( n = 26) were measured using specific human ORM1, TF, and PAI‐1 enzyme‐linked immunosorbent assay (ELISA) kits. (D) Oxygenation index, expressed as the ratio of arterial oxygen partial pressure to oxygen concentration (P/F), in ARDS patients ( n = 28) and non‐ARDS patients ( n = 26). Correlations between BALF concentrations of ORM1 and those of (E) TF, (F) PAI‐1, and (G) P/F ratio in patients with ARDS are shown. Data represent mean ± SD. Significance in (A–D) was calculated using an independent t test; significance in (A–D) was calculated using one‐way analysis of variance (ANOVA) with Scheffé's post hoc test, and (E–G) were evaluated with Pearson's correlation coefficients. **** p < 0.0001.

Article Snippet: The slides were blocked with goat serum (Solarbio, Beijing, China) at room temperature for 1 h and incubated with ORM1 antibody (1:100 dilution; Proteintech Group Inc., Wuhan, China) overnight at 4°C.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay

Proteomic analysis of the synovial fluid (SF) samples from patients with different stages of temporomandibular joint osteoarthritis (TMJOA). A) Flow diagram for patient inclusion and grouping. B) Photograph showing joint fluid collection during arthroscopic surgery. C) Flow diagram for the proteomic analysis of SF samples. D) Principal component analysis of SF samples. E) Top 10 genes that showed an upward trend and top 10 genes that showed a downward trend in the three groups. F) Orosomucoid 1 (ORM1) expression in patients with different grades of TMJOA, including Mild (n = 21), Moderate (n = 27), and Severe (n = 15) groups. Data is expressed as mean ± SD and analyzed using one‐way analysis of variance (ANOVA) followed by Tukey's post‐hoc test. G) ORM1 expression in patients with pain (n = 30) or without pain (n = 26). Data is expressed as mean ± SD and analyzed using unpaired Student's t test (two‐tailed). H) ORM1 expression in patients with different degrees of maximum interincisal opening (MIO). Data in MIO ≤ 25 mm (n = 10), MIO 26–35 mm (n = 20), and MIO ≥ 36 mm (n = 29) groups are expressed as mean ± SD and analyzed using one‐way ANOVA followed by Tukey's post‐hoc test. I) ORM1 expression in patients with sleep bruxism (n = 26) or without sleep bruxism (n = 23). Data is expressed as mean ± SD and analyzed using unpaired Student's t test (two‐tailed). J) ORM1 concentration in SF samples detected by ELISA assay in Mild (n = 5), Moderate (n = 5), and Severe (n = 5) groups. Data is expressed as mean ± SD and analyzed using one‐way ANOVA followed by Tukey's post‐hoc test. FOT, fraction of the total; * p < 0.05.

Journal: Advanced Science

Article Title: Orosomucoid 1 Ameliorates Temporomandibular Joint Osteoarthritis by Maintaining Cartilage Homeostasis

doi: 10.1002/advs.202500028

Figure Lengend Snippet: Proteomic analysis of the synovial fluid (SF) samples from patients with different stages of temporomandibular joint osteoarthritis (TMJOA). A) Flow diagram for patient inclusion and grouping. B) Photograph showing joint fluid collection during arthroscopic surgery. C) Flow diagram for the proteomic analysis of SF samples. D) Principal component analysis of SF samples. E) Top 10 genes that showed an upward trend and top 10 genes that showed a downward trend in the three groups. F) Orosomucoid 1 (ORM1) expression in patients with different grades of TMJOA, including Mild (n = 21), Moderate (n = 27), and Severe (n = 15) groups. Data is expressed as mean ± SD and analyzed using one‐way analysis of variance (ANOVA) followed by Tukey's post‐hoc test. G) ORM1 expression in patients with pain (n = 30) or without pain (n = 26). Data is expressed as mean ± SD and analyzed using unpaired Student's t test (two‐tailed). H) ORM1 expression in patients with different degrees of maximum interincisal opening (MIO). Data in MIO ≤ 25 mm (n = 10), MIO 26–35 mm (n = 20), and MIO ≥ 36 mm (n = 29) groups are expressed as mean ± SD and analyzed using one‐way ANOVA followed by Tukey's post‐hoc test. I) ORM1 expression in patients with sleep bruxism (n = 26) or without sleep bruxism (n = 23). Data is expressed as mean ± SD and analyzed using unpaired Student's t test (two‐tailed). J) ORM1 concentration in SF samples detected by ELISA assay in Mild (n = 5), Moderate (n = 5), and Severe (n = 5) groups. Data is expressed as mean ± SD and analyzed using one‐way ANOVA followed by Tukey's post‐hoc test. FOT, fraction of the total; * p < 0.05.

Article Snippet: Enzyme‐linked immunosorbent assay (ELISA) was performed to measure the concentration of ORM1 in SF samples by an ELISA kit (KE00137; Proteintech).

Techniques: Expressing, Two Tailed Test, Concentration Assay, Enzyme-linked Immunosorbent Assay